CREB3L2 and neoplasm: Transwell migration and matrix gel invasion assays demonstrated that suppression of CREB3L2 reduced cell migration and invasion, ultimately restoring the anti-tumor effects of lenvatinib in vitro (Fig. 7D and Supplementary Fig. S5D, E).